The role of molecular tests in acute myelogenous leukemia treatment decisions

Current Hematologic Malignancy Reports

Volumn 5, Issue 2, 2010, Pages 109-117

  Motyckova, Gabriela ^a   Stone, Richard M ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Acute myeloid leukemia; FLT3; Genetics; NPM1; Prognosis

Indexed keywords

ANTHRACYCLINE; CCAAT ENHANCER BINDING PROTEIN ALPHA; CD135 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; CYTARABINE; MICRORNA; MIXED LINEAGE LEUKEMIA PROTEIN; NUCLEOPHOSMIN; RAS PROTEIN; TRANSCRIPTION FACTOR ERG; WT1 PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; BAALC GENE; CLINICAL DECISION MAKING; CYTOGENETICS; DNA MICROARRAY; GENE EXPRESSION PROFILING; GENE MUTATION; GENE OVEREXPRESSION; GENE TRANSLOCATION; HUMAN; MN1 GENE; ONCOGENE C KIT; PROGNOSIS; REVIEW; TUMOR GENE;

ACUTE DISEASE; GENE EXPRESSION PROFILING; HUMANS; KARYOTYPING; LEUKEMIA, MYELOID; MICRORNAS; MUTATION; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 77954621530     PISSN: 15588211     EISSN: 1558822X     Source Type: Journal    
DOI: 10.1007/s11899-010-0049-7     Document Type: Review

References (57)

1. Jemal A, Siegel R, Ward E, et al.: Cancer statistics, 2008. CA Cancer J Clin 2008, 58(2):71-96.
2. • Tallman MS, Gilliland DG, and Rowe JM: Drug therapy for acute myeloid leukemia. [Erratum appears in Blood 2005, 106 (7):2243.]
3. Blood 2005, 106(4):1154-1163.
4. • Mrozek K, Marcucci G, Paschka P, et al.: Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: Are we ready for a prognostically prioritized molecular classification? Blood 2007, 109 (2):431-448. This article is a detailed review of the prognostic impact of gene mutations in AML.
5. Mrozek K, Heerema NA, Bloomfield CD: Cytogenetics in acute leukemia. Blood Rev 2004, 18(2):115-136.
6. •• Schlenk RF, Dohner K, Krauter J, et al.: Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008, 358(18):1909-1918. This article is a meta-analysis of four prospective clinical trials describing the prognostic impact of gene mutations in AML. The analysis showed that allogeneic SCT may offer a survival advantage to AML patients, except for those with NPM1 mutation in the setting of FLT3 wild-type status.
7. Abu-Duhier FM, Goodeve AC, Wilson GA, et al.: Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia. Br J Haematol 2001, 113(4):983-988.
8. Reindl C, Bagrintseva K, Vempati S, et al.: Point mutations in the juxtamembrane domain of FLT3 define a new class of activating mutations in AML. Blood 2006, 107(9):3700-3707.
9. Frohling S, Scholl C, Levine RL, et al.: Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles. Cancer Cell 2007, 12(6):501-513.
10. Kottaridis PD, Gale RE, Frew ME, et al.: The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 2001, 98 (6):1752-1759.
11. Bienz M, Ludwig M, Leibundgut EO, et al.: Risk assessment in patients with acute myeloid leukemia and a normal karyotype. [Erratum appears in Clin Cancer Res 2005, 11(15):5659.]
12. Hayakawa F, Towatari M, Kiyoi H, et al.: Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines. Oncogene 2000, 19(5):624-631.
13. Whitman SP, Archer KJ, Feng L, et al.: Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a Cancer and Leukemia Group B study. Cancer Res 2001, 61(19):7233-7239.
14. Thiede C, Steudel C, Mohr B, et al.: Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood 2002, 99(12):4326-4335.
15. Meshinchi S, Alonzo TA, Stirewalt DL, et al.: Clinical implications of FLT3 mutations in pediatric AML. Blood 2006, 108 (12):3654-3661.
16. • Gale RE, Green C, Allen C, et al.: The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood 2008, 111(5):2776-2784. This article describes the prognostic impact of NPM1 mutations, FLT3-ITD mutant levels, and ITD size.
17. Kayser S, Schlenk RF, Londono MC, et al.: Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome. Blood 2009, 114(12):2386-2392.
18. Breitenbuecher F, Schnittger S, Grundler R, et al.: Identification of a novel type of ITD mutations located in nonjuxtamembrane domains of the FLT3 tyrosine kinase receptor. Blood 2009, 113 (17):4074-4077.
19. Stirewalt DL, Kopecky KJ, Meshinchi S, et al.: Size of FLT3 internal tandem duplication has prognostic significance in patients with acute myeloid leukemia. Blood 2006, 107(9):3724-3726.
20. Meshinchi S, Stirewalt DL, Alonzo TA, et al.: Structural and numerical variation of FLT3/ITD in pediatric AML. Blood 2008, 111(10):4930-4933.
21. Ponziani V, Gianfaldoni G, Mannelli F, et al.: The size of duplication does not add to the prognostic significance of FLT3 internal tandem duplication in acute myeloid leukemia patients. Leukemia 2006, 20(11):2074-2076.
22. Ozeki K, Kiyoi H, Hirose Y, et al.: Biologic and clinical significance of the FLT3 transcript level in acute myeloid leukemia. Blood 2004, 103(5):1901-1908.
23. Bullinger L, Dohner K, Bair E, et al.: Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. N Engl J Med 2004, 350(16):1605-1616.
24. • Whitman SP, Ruppert AS, Radmacher MD, et al.: FLT3 D835/ I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications. Blood 2008, 111(3):1552- 1559. This study describes a negative prognostic impact of FLT3- TKD mutation in AML, in contrast to the findings of Mead et al. [24•].
25. • Mead AJ, Linch DC, Hills RK, et al.: FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia. Blood 2007, 110(4):1262-1270. This article describes FLT3-TKD mutations and their favorable prognosis in AML, in contrast to the findings of Whitman et al. [23•].
26. Thiede C, Koch S, Creutzig E, et al.: Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). Blood 2006, 107(10):4011-4020.
27. Falini B, Nicoletti I, Bolli N, et al.: Translocations and mutations involving the nucleophosmin (NPM1) gene in lymphomas and leukemias. Haematologica 2007, 92(4):519-532.
28. Falini B, Nicoletti I, Martelli MF, et al.: Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical features. Blood 2007, 109(3):874-885.
29. • Marcucci G, Maharry K, Radmacher MD, et al.: Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: A Cancer and Leukemia Group B Study. J Clin Oncol 2008, 26 (31):5078-5087. This article describes prognostic impact of CEBPa mutations in AML
30. Baldus CD, Tanner SM, Ruppert AS, et al.: BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: A Cancer and Leukemia Group B Study. Blood 2003, 102(5):1613-1618.
31. Marcucci G, Baldus CD, Ruppert AS, et al.: Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B study. J Clin Oncol 2005, 23(36):9234-9242.
32. • Marcucci G, Maharry K, Whitman SP, et al.: High expression levels of the ETS-related gene, ERG, predict adverse outcome and improve molecular risk-based classification of cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B Study. J Clin Oncol 2007, 25(22):3337-3343. This study describes the negative prognostic impact of ERG overexpression in AML.
33. Langer C, Marcucci G, Holland KB, et al.: Prognostic importance of MN1 transcript levels, and biologic insights from MN1- associated gene and microRNA expression signatures in cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol 2009, 27(19):3198-3204.
34. Heuser M, Beutel G, Krauter J, et al.: High meningioma 1 (MN1) expression as a predictor for poor outcome in acute myeloid leukemia with normal cytogenetics. Blood 2006, 108(12):3898-3905.
35. Metzeler KH, Dufour A, Benthaus T, et al.: ERG expression is an independent prognostic factor and allows refined risk stratification in cytogenetically normal acute myeloid leukemia: a comprehensive analysis of ERG, MN1, and BAALC transcript levels using oligonucleotide microarrays. J Clin Oncol 2009, 27(30):5031-5038.
36. Mills K: Gene expression profiling for the diagnosis and prognosis of acute myeloid leukaemia. Front Biosci 2008, 13:4605-4616.
37. Whitman SP, Liu S, Vukosavljevic T, et al.: The MLL partial tandem duplication: evidence for recessive gain-of-function in acute myeloid leukemia identifies a novel patient subgroup for molecular-targeted therapy. Blood 2005, 106(1):345-352.
38. Young A, Lyons J, Miller AL, et al.: Ras signaling and therapies. Adv Cancer Res 2009, 102:1-17.
39. • Neubauer A, Maharry K, Mrozek K, et al.: Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine: a Cancer and Leukemia Group B study. J Clin Oncol 2008, 26(28):4603-4609. This study shows an improved prognosis of AML patients with Ras mutations receiving high-dose cytarabine in consolidation, when compared with lower-dose cytarabine or patients with wild-type Ras AML.
40. Advani AS, Rodriguez C, Jin T, et al.: Increased C-kit intensity is a poor prognostic factor for progression-free and overall survival in patients with newly diagnosed AML. Leuk Res 2008, 32(6):913-918.
41. Cairoli R, Beghini A, Grillo G, et al.: Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study. Blood 2006, 107(9):3463-3468.
42. Boissel N, Leroy H, Brethon B, et al.: Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML). Leukemia 2006, 20 (6):965-970.
43. • Paschka P, Marcucci G, Ruppert AS, et al.: Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol 2008, 26(28):4595-4602. This study describes the negative prognostic impact of WT1 mutations in AML.
44. Gaidzik VI, Schlenk RF, Moschny S, et al.: Prognostic impact of WT1 mutations in cytogenetically normal acute myeloid leukemia: a study of the German-Austrian AML Study Group. Blood 2009, 113(19):4505-4511.
45. • Tavernier-Tardy E, Cornillon J, Campos L, et al.: Prognostic value of CXCR4 and FAK expression in acute myelogenous leukemia. Leuk Res 2009, 33(6):764-768. This article shows the negative prognostic effect of CXCR4 overexpression in AML.
46. Burger JA, Spoo A, Dwenger A, et al.: CXCR4 chemokine receptors (CD184) and a4β1 integrins mediate spontaneous migration of human CD34+ progenitors and acute myeloid leukaemia cells beneath marrow stromal cells (pseudoemperipolesis). Br J Haematol 2003, 122(4):579-589.
47. Zeng Z, Shi YX, Samudio IJ, et al.: Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML. Blood 2009, 113 (24):6215-6224.
48. Garzon R, Garofalo M, Martelli MP, et al.: Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin. Proc Natl Acad Sci U S A 2008, 105(10):3945-3950
49. Jongen-Lavrencic M, Sun SM, Dijkstra MK, et al.: MicroRNA expression profiling in relation to the genetic heterogeneity of acute myeloid leukemia. Blood 2008, 111(10):5078-5085.
50. Garzon R, Volinia S, Liu CG, et al.: MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood 2008, 111(6):3183-3189.
51. Bullinger L, Dohner K, Kranz R, et al.: An FLT3 gene-expression signature predicts clinical outcome in normal karyotype AML. Blood 2008, 111(9):4490-4495.
52. Mrozek K, Radmacher MD, Bloomfield CD, et al.: Molecular signatures in acute myeloid leukemia. Curr Opin Hematol 2009, 16(2):64-69.
53. Gale RE, Hills R, Kottaridis PD, et al.: No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1135 patients, excluding acute promyelocytic leukemia, from the UK MRC AML10 and 12 trials. Blood 2005, 106(10):3658-3665.
54. Stone RM, DeAngelo DJ, Klimek V, et al.: Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood 2005, 105(1):54-60. (Pubitemid 40053063)
55. Verstovsek S, Tefferi A, Cortes J, et al.: Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis. Clin Cancer Res 2008, 14(12):3906-3915.
56. Metzelder S, Wang Y, Wollmer E, et al.: Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation. Blood 2009, 113(26):6567-6571.
57. The US National Institutes of Health. Available at http://www. clinicaltrials.gov. Accessed January 2010.